TuHURA Biosciences (HURA) has appointed Craig Tendler, M.D. to its Board of Directors effective March 10, 2025. During his tenure at Johnson & Johnson (JNJ), Dr. Tendler and his team worked in collaboration with the FDA and the European Medicines Agency to secure the worldwide approvals of transformational treatments in prostate cancer, hematologic malignancies as well as for lung and bladder cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA: